• SHOP
      • COMBOS
      • TESTIMONIALS
      • CART
      • INGREDIENTS
        • 2-DEOXY-D-GLUCOSE (2DG)
        • ACACIA CYANOPHYLLA FLOWER
        • ACORI GRAMINEI RHIZOMA
        • AEGLE MARMELOS CORREA
        • AGARICUS BLAZEI
        • AGED GARLIC EXTRACT
        • AFRAMOMUM MELEGUETA
        • ALOE ARBORESCENS
        • ALBIZIA
        • ALPINIA OFFICINARUM
        • ALTERNANTHERA SESSILIS
        • AMERICAN GINSENG
        • AMYGDALIN
        • ANACYCLUS PYRETHRUM
        • ANGELICA ARCHANGELICA
        • ANGELICA SINENSIS
        • ANTRODIA
        • ARTICHOKE LEAF
        • ARTOCARPIN
        • AJUGA TURKESTANICA
        • ASHWAGANDHA
        • ASPALATHIN
        • ASTRAGALUS COMPLANATUS
        • AVENA SATIVA
        • BACOPA MONNIERI
        • BAVACHIN
        • BEE POLLEN
        • BETULINIC ACID
        • BOSWELLIC ACID
        • BREVILIN A
        • CAMPESTEROL
        • CAPSAICIN
        • CARCININE
        • CASTICIN
        • CHRYSIN
        • CIANIDANOL
        • CINNAMOMUM ZEYLANICUM
        • CITRULLUS COLOCYNTHIS
        • CITRUS RETICULATA PEEL
        • CODONOPSIS
        • CONJUGATED LINOLEIC ACID
        • COSTUNOLIDE
        • CYANIDIN
        • CUCURBITACIN D
        • DAIDZEIN
        • DECURSIN
        • DELPHINIDIN
        • DIGITALIS PURPREA (DIGOXIN)
        • DIOSMIN
        • ECKLONIA CAVA
        • ELLAGIC ACID
        • EMBELIN
        • ERIODICTYOL
        • GALLIC ACID
        • GLYCITEIN
        • GLYCYRRHIZIN
        • HYPERFORIN
        • ICARIIN
        • ISORHAMNETIN
        • ISOORIENTIN
        • ISOVITEXIN
        • JACEOSIDIN
        • KAEMPFEROL
        • KIGELIA AFRICANA
        • KURARINONE
        • LEMON BALM
        • LICORICIDIN
        • LIPOIC ACID
        • LUPEOL
        • MAGNOLOL
        • MENAQUINONE 4
        • MULBERRY LEAF
        • NARINGENIN
        • NOBILETIN
        • OLEACEIN
        • OLEANOLIC ACID
        • OLIVE OIL
        • ORIDONIN
        • PARTHENOLIDE
        • PHLOROGLUCINOL
        • PHLORIZIN
        • PICEATANNOL
        • PRISTIMERIN
        • PROANTHOCYANIDINS
        • PROCYANIDIN B3
        • PSEUDOLARIC ACID B
        • PTEROSTILBENE
        • RUTIN
        • SOLIDAGO VIRGAUREA
        • TANGERETIN
        • TARAXASTEROL
        • TRICHOSTATIN A
        • WEDELOLACTONE
        • WOGONIN
        • YERBA MATE
      • ABOUT
      • SCIENTIFIC STUDIES
        • ADAPTOGENS
        • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
        • ADDICTION & THE BRAIN
        • ADDICTION & STRESS
        • ADDICTION WITHDRAWAL
        • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
        • ADIPOCYTE DIFFERENTIATION
        • ADROPIN
        • ALLERGIES & CYTOKINES
        • ALDOSTERONE & OBESITY/HYPERTENSION
        • ALZHEIMER’S, DEMENTIA, PARKINSON’S
        • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
        • ADVANCED GLYCATION END PRODUCTS (AGES)
        • ADDICTION TREATMENT
        • ADDICTION & DOPAMINE
        • AMPK
        • ANTI AGING
        • ANTIAGING EFFECTS OF COFFEE
        • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
        • ANTI-APOPTOTIC PATHWAYS
        • ANTI ATHEROGENIC
        • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
        • ANTI CARIOGENIC (Protecting From Tooth Decay)
        • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
        • ANTI GLYCATIVE
        • ANTI GLYCATION AGENTS
        • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
        • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
        • ANTI WRINKLE AGENTS
        • ANXIOGENIC
        • ANXIOLYTIC
        • APOPTOSIS
        • APOPTOSIS IN 3T3-L1
        • AUTOPHAGY
        • BCL-2
        • BCL-W
        • BCL-XL
        • BDNF
        • BECLIN-1 & AUTOPHAGY
        • BH3 MIMETICS
        • BIM aka BCL2L11
        • BIOMIMETIC HYDROXYAPATITE
        • BMI-1
        • BPA & OBESITY
        • BRASSINOSTEROIDS
        • CALORIE RESTRICTION
        • CALORIE RESTRICTION & LIFESPAN EXTENSION
        • CARBAMYLATION
        • CARBONYL SCAVENGER
        • CARBONYL STRESS
        • CARDIOPROTECTIVE AGENTS
        • CARDIAC GLYCOSIDES
        • CATALASE
        • CELL CYCLE ARREST
        • CENTENARIANS
        • CDK5
        • CHOLESTEROL EFFLUX
        • COGNITIVE ENHANCEMENT
        • COLD SHOCK PROTEINS
        • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
        • CONDITIONED PLACE PREFERENCE
        • CORTICOTROPIN RELEASING FACTOR
        • COSMECEUTICAL
        • CRYOTHERAPY
        • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
        • CYP2E1
        • CYTOKINES IN PAIN, INFLAMMATION & AGING
        • DAF-16
        • DEPERSONALIZATION
        • DIABETES & CANCER
        • DIHYDROTESTOSTERONE (DHT)
        • DNA METHYLATION & AGING
        • DNA REPAIR
        • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
        • DRY FASTING AND FLUID RESTRICTION FASTING
        • DYNORPHIN
        • ELLAGITANNINS
        • ENDOCRINE DISRUPTING CHEMICALS
        • ENLARGED HEART AND CARDIOMEGALY
        • EPIGENETIC ALTERATIONS
        • EPIGENETIC MODIFIERS
        • EPINEPHRINE
        • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
        • EXCITOXICITY & THE BRAIN
        • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
        • EXTRACELLULAR MICROVESICLES
        • EXTENDS LIFESPAN
        • EXTINCTION TRAINING
        • FASTING & THE BRAIN
        • FASTING & CANCER
        • FASTING MIMICKING DIET
        • FEAR EXTINCTION
        • FGF21
        • FLAVONES
        • GABA (γ-AMINOBUTYRIC ACID)
        • GALLOTANNINS
        • GLUCONEOGENESIS
        • GLUCOCORTICOID RECEPTOR ACTIVATION
        • GLUTAMATE & BRAIN
        • GLYCATION
        • GUT BRAIN AXIS
        • GYPENOSIDE
        • KLOTHO
        • K OPIOD RECEPTOR & ADDICTION
        • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
        • FGF21
        • FOXO3
        • FOXO4
        • HALLMARKS OF AGING
        • HAIR GROWTH
        • HAIR REGENERATION
        • HAIR REPIGMENTATION
        • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
        • HMGB1
        • HORMESIS
        • HPA AXIS
        • HSP70, THE ANTI-AGING PROTEIN
        • HSP90 INHIBITORS
        • HYPERGLYCEMIA
        • HYPERALGESIA
        • HYPERINSULINEMIA
        • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
        • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
        • HYPOCRETIN OREXIN
        • IKK
        • IL-6/STAT3
        • IRISIN
        • ISOFLAVONES
        • IMMUNOSENESCENCE
        • INHIBITION OF ADVANCED GLYCATION END PRODUCTS
        • INCREASE PROTEIN SYNTHESIS
        • INCREASES SPERMATOGENESIS
        • INFECTOBESITY
        • INFLAMMATION & ANXIETY
        • INFLAMMATION & CANCER
        • INFLAMMATION & DEPRESSION
        • INFLAMMATION & OBESITY
        • INFLAMMAGING
        • INHIBITION OF RENAL GLUCOSE REABSORPTION
        • INSULIN & AGING
        • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
        • INSULIN & MTOR
        • INSULIN & OBESITY
        • INSULIN OXIDATIVE STRESS
        • INTERMITTENT FASTING
        • JAK INHIBITION ALLEVIATES SASP
        • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
        • KETONE BODIES
        • KETOGENIC DIET
        • LACTOBACILLUS REUTERI
        • LACTOFERRIN
        • LEYDIG CELL STEROIDOGENESIS
        • LIFESPAN EXTENSION
        • LIVER REGENERATION
        • LIPOLYTIC AGENTS
        • LIPID DROPLETS
        • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
        • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
        • MATRIX METALLOPROTEINASES (MMPs)
        • MCL-1
        • MDM2 INHIBITION AS SASP INHIBITOR
        • MEDICINAL MUSHROOMS
        • MEDITERRANEAN DIET
        • METABOLIC REPROGRAMMING
        • METABOLIC SYNDROME
        • METHIONINE RESTRICTION
        • MITOCHONDRIAL UNCOUPLING
        • MONKEYPOX
        • MSG (MONOSOSODIUM GLUTAMATE)
        • MUSCLE FORCE PRODUCTION
        • MUSCLE ATROPHY (PREVENTING)
        • MYOGENESIS
        • MYOSTATIN INHIBITION
        • MYOSTATIN INHIBITION PRESERVES MUSCLE
        • mTORC2
        • mTOR: THE RAPID AGING PATHWAY
        • NATURAL ANTICOAGULANTS
        • NATURAL AROMATASE INHIBITORS
        • NEUROGENESIS (GROWING NEW BRAIN CELLS)
        • NEUROCHEMISTRY OF ADDICTION
        • NEUROPLASTICITY
        • NEUROINFLAMMATION
        • NEUROPROTECTIVE AGENTS
        • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
        • NMDA & ANXIETY & DEPRESSION
        • NMDA RECEPTOR & FEAR
        • NON OPIOD ANALGESICS
        • NOOTROPICS
        • NORADRENERGIC
        • NOREPINEPHRINE
        • NRF2: MASTER REGULATOR OF THE AGING PROCESS
        • NF-KB
        • NUTRACEUTICAL
        • OBESOGENS
        • ONCOGENE ACTIVATION INDUCED SENESCENCE
        • ORGANOTINS
        • OVERNUTRITION
        • OXIDATIVE STRESS & AGING
        • P16INK4A
        • P38MAPK
        • P53: TUMOR SUPRESSOR
        • PERIODONTITIS
        • PHOSPHATIDYLINOSITOL 3 KINASE
        • PHYTOCHEMICALS
        • PHYTOSTEROLS
        • PHYTOSTANOLS
        • PHYTOECDYSTEROIDS
        • PROANTHOCYANIDINS
        • PROTEIN CARBONYLATION
        • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
        • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
        • PPARY2
        • PREMATURE SENESCENCE
        • PREVENTING SKIN AGING
        • PUFAS
        • PURGATIVES
        • RADIATION EXTRACT
        • RAPAMYCIN (MTOR INHIBITION)
        • RED WINE
        • RENAL (KIDNEY) PROTECTIVE AGENTS
        • REMINERALIZATION OF TEETH
        • REMYELINATION
        • REPAIR OF DNA BREAKS “DOUBLE STRAND”
        • RESTORE INSULIN SENSITIVITY
        • REVERSAL OF OBESITY
        • SASP & ADIPOSE TISSUE
        • SEX HORMONE BINDING GLOBULIN
        • SENESCENT CELLS, SASP & SENOLYTICS
        • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
        • SGLT2 INHIBITORS
        • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
        • SHBG
        • SIRT1
        • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
        • SKIN ELASTICITY
        • SKIN PHOTOAGING (Preventing & Repairing)
        • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
        • SIRT1 & LONGEVITY
        • SMALLPOX
        • SUGAR & AGING
        • STAR PROTEIN
        • STAT3
        • STEM CELL EXHAUSTION
        • STEM CELL REGENERATION
        • STEM CELL THERAPY
        • STIMULATED LIPOLYSYS
        • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
        • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
        • STRESS & AGING
        • STRESS & THE BRAIN
        • TELOMERE SHORTENING & PREMATURE AGING
        • TIME RESTRICTED FEEDING
        • THROMBOLYTICS (PLANT BASED)
        • TRAUMATIC BRAIN INJURY (HEALING)
        • TRYPTOPHAN HYDROXYLASE 2
        • VISCERAL ADIPOSITY
        • XENOBIOTICS
        • XENOESTROGEN
      • HOME
      • CONTACT
      • TELEGRAM PORTAL
      • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
      • The Ultimate Dry Fasting Resource
      0
      blank
      ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      January 10, 2021
      blank
      Insulin & Aging
      February 5, 2021
      1. … . Initial studies were promising (Miserendino et al 1990). Infusion of APV prior to learning blocked fear conditioning, but infusion proior to testing had no effect. NMDA
      2. … blockade of NMDA receptors induces epigenetic abnormalities in the adult medial prefrontal cortex: possible involvement in memory impairment in trace fear …
      3. … in rats is mediated by neurons in the deep layers of the superior colliculus/deep mesencephalic nucleus of the rostral midbrain through the glutamate non-NMDA …
      4. … of an NR2B-selective or an NR2A-preferring NMDA receptor antagonist differentially influence fear conditioning and expression in the fear-potentiated startle test
      5. A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior
      6. A NMDA receptor antagonist, MK-801 impairs consolidating extinction of auditory conditioned fear responses in a Pavlovian model
      7. A risk variant for alcoholism in the NMDA receptor affects amygdala activity during fear conditioning in humans
      8. Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist D, L-2-amino-5-phosphonovaleric acid to the …
      9. Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala
      10. Acquisition, extinction, and reinstatement of Pavlovian fear conditioning: the roles of the NMDA receptor and nitric oxide
      11. Activity-induced synaptic delivery of the GluN2A-containing NMDA receptor is dependent on endoplasmic reticulum chaperone Bip and involved in fear …
      12. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear …
      13. Alcohol inhibition of the NMDA receptor function, long-term potentiation, and fear learning requires striatal-enriched protein tyrosine phosphatase
      14. Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats
      15. Amygdalar NMDA receptors are critical for the expression of multiple conditioned fear responses
      16. An appetitive experience after fear memory destabilization attenuates fear retention: involvement GluN2B-NMDA receptors in the Basolateral Amygdala Complex
      17. An appetitive experience after fear memory destabilization attenuates fear retention: involvement GluN2B-NMDA receptors in the Basolateral Amygdala Complex.
      18. An NMDA–receptor antagonist, MK-801 blocks the suppressive vasopressin response to fear-but not to anxiety-related stimuli in the rat.
      19. Aquaporin-4 deficiency facilitates fear memory extinction in the hippocampus through excessive activation of extrasynaptic GluN2B-containing NMDA receptors
      20. Are fear memories made and maintained by the same NMDA receptor-dependent mechanisms?
      21. ASIC1a regulates ventral hippocampal-infralimbic prefrontal plasticity and fear extinction via BDNF-NMDA receptor signaling
      22. Bed nucleus of the stria terminalis NMDA receptors and nitric oxide modulate contextual fear conditioning in rats
      23. Beyond attention: The role of amygdala NMDA receptors in fear conditioning
      24. Blockade of Cav2. 1-mediated NMDA receptor signaling disrupts conditioned fear extinction
      25. Blockade of NMDA receptors in the amygdala prevents latent inhibition of fear-conditioning
      26. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala
      27. Brief neonatal maternal separation alters extinction of conditioned fear and corticolimbic glucocorticoid and NMDA receptor expression in adult rats
      28. Close linkage between calcium/calmodulin kinase II α/β and NMDA‐2A receptors in the lateral amygdala and significance for retrieval of auditory fear conditioning
      29. Complex effects of NMDA receptor antagonist APV in the basolateral amygdala on acquisition of two-way avoidance reaction and long-term fear memory
      30. Conditioning-strength dependent involvement of NMDA NR2B subtype receptor in the basolateral nucleus of amygdala in acquisition of auditory fear memory
      31. Consolidation of auditory fear memories formed by weak unconditioned stimuli requires NMDA receptor activation and de novo protein synthesis in the …
      32. Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex
      33. Decrease in NMDA receptor-signalling activity in the anterior cingulate cortex diminishes defensive behaviour and unconditioned fear-induced antinociception elicited …
      34. Differential involvement of amygdala and cortical NMDA receptors activation upon encoding in odor fear memory
      35. Differential involvement of amygdalar NMDA receptors across variants of contextual fear conditioning in adolescent rats
      36. Differential involvement of amygdalar NMDA receptors in variants of adolescent contextual fear conditioning
      37. Differentiating the contributions of NMDA receptor-mediated synaptic plasticity in basal and lateral nuclei of the amygdala during Pavlovian fear conditioning
      38. Dorsal hippocampus and classical fear conditioning to tone and context in rats: Effects of local NMDA‐receptor blockade and stimulation
      39. Dorsal hippocampus NMDA receptors differentially mediate trace and contextual fear conditioning
      40. Effect of the NMDA antagonist MK-801 on latent inhibition of fear conditioning
      41. Effects of agonists and antagonists of NMDA and ACh receptors on plasticity of bat auditory system elicited by fear conditioning
      42. Effects of an NMDA–receptor antagonist, MK-801 on emotional memory associated with neurohypophysial responses to fear or anxiety stimuli in rats
      43. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice
      44. Effects of REM deprivation and an NMDA agonist on the extinction of conditioned fear
      45. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD
      46. Elucidating the mechanisms of fear extinction in developing animals: a special case of NMDA receptor-independent extinction in adolescent rats
      47. Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning
      48. Estradiol-induced enhancement of fear extinction in female rats: The role of NMDA receptor activation
      49. Estradiol-induced enhancement of fear extinction in female rats: the role of NMDA receptor activation Running title: Estradiol, NMDAr activation, and fear …
      50. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala
      51. Extinction of fear-potentiated Startle: Blockade by Infusion of an NMDA Antagonist into the Amygdala
      52. fear conditioning performance and NMDA receptor subtypes: NR2A differential expression in the striatum
      53. fear memory extinction accelerated by simultaneous activation of GABA (B) and NMDA receptors
      54. fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageing
      55. GABA and NMDA receptors in CRF neurons have opposing effects in fear acquisition and anxiety in central amygdala vs. bed nucleus of the stria terminalis
      56. Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats
      57. Hippocampal NMDA receptor blockade impairs CREB phosphorylation in amygdala after contextual fear conditioning
      58. Hippocampal NMDA receptor subunits differentially regulate fear memory formation and neuronal signal propagation
      59. Hippocampal NMDA receptors are necessary for auditory trace fear conditioning measured with conditioned hypoalgesia in rats
      60. Hypofunction of the dorsal hippocampal NMDA receptors impairs retrieval of memory to partially presented foreground context in a single-trial fear conditioning in rats
      61. Impairment of conditioned contextual fear of C57BL/6J mice by intracerebral injections of the NMDA receptor antagonist APV
      62. Induction-and conditioning-protocol dependent involvement of NR2B-containing NMDA receptors in synaptic potentiation and contextual fear memory in the …
      63. Infusion of the NMDA receptor antagonist, DL-APV, into the basolateral amygdala disrupts learning to fear a novel and a familiar context as well as relearning to fear …
      64. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle
      65. Injections of the NMDA receptor antagonist aminophosphonopentanoic acid into the lateral nucleus of the amygdala block the expression of fear-potentiated startle …
      66. Interaction between glutamatergic–NMDA and cholinergic–muscarinic systems in classical fear conditioning
      67. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning
      68. Involvement of NMDA receptors within the amygdala in short-versus long-term memory for fear conditioning as assessed with fear-potentiated startle.
      69. Lack of a temporal gradient of retrograde amnesia following NMDA-induced lesions of the basolateral anygdala assessed with the fear-potentiated startle paradigm.
      70. Latent inhibition of cued fear conditioning: an NMDA receptor‐dependent process that can be established in the presence of anisomycin
      71. Loss of NMDA receptor function in corticotrophin-releasing factor neurons sex-dependently enhances fear and increases sensitivity to social stress, yet reduces social …
      72. Mapping and deciphering neural codes of NMDA receptor-dependent fear memory engrams in the hippocampus
      73. Neonatal ethanol exposure impairs trace fear conditioning and alters NMDA receptor subunit expression in adult male and female rats
      74. Neonatal treatment with a competitive NMDA antagonist results in response-specific disruption of conditioned fear in preweanling rats
      75. Newly acquired and reactivated contextual fear memories are more intense and prone to generalize after activation of prelimbic cortex NMDA receptors
      76. Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the …
      77. Nitric oxide signalling in the basolateral complex of the amygdala: an extension of NMDA receptor activation during Pavlovian fear conditioning and expression
      78. NMDA and AMPA/kainate glutamatergic receptors in the prelimbic medial prefrontal cortex modulate the elaborated defensive behavior and innate fear-induced …
      79. NMDA and dopaminergic contributions to context fear memory reconsolidation
      80. NMDA and muscarinic receptor modulation of latent learning in Pavlovian fear conditioning.
      81. NMDA currents and receptor protein are downregulated in the amygdala during maintenance of fear memory
      82. NMDA GluN2A and GluN2B receptors play separate roles in the induction of LTP and LTD in the amygdala and in the acquisition and extinction of conditioned fear
      83. NMDA processes mediate anterograde amnesia of contextual fear conditioning induced by hippocampal damage: immunization against amnesia by context …
      84. NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats
      85. NMDA receptor antagonist MK-801 blocks learning of conditioned stimulus-unconditioned stimulus contiguity but not fear of conditioned stimulus in goldfish …
      86. NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57Bl/6 mice
      87. NMDA receptor mediated expression of Arc in dorsal and ventral hippocampus contributes to the acquisition of contextual and trace fear conditioning
      88. NMDA receptor-and ERK-dependent histone methylation changes in the lateral amygdala bidirectionally regulate fear memory formation
      89. NMDA receptor-dependent LTD is required for consolidation but not acquisition of fear memory
      90. NMDA receptor-mediated Arc expression in dorsal and ventral hippocampus contributes to the acquisition of trace and contextual fear conditioning
      91. NMDA receptors and fear extinction: implications for cognitive behavioral therapy
      92. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral …
      93. NMDA receptors and the ontogeny of post‐shock and retention freezing during contextual fear conditioning
      94. NMDA receptors are critical for unleashing consolidated auditory fear memories
      95. NMDA receptors are essential for the acquisition, but not expression, of conditional fear and associative spike firing in the lateral amygdala
      96. NMDA receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory
      97. NMDA receptors in the CeA and BNST differentially regulate fear conditioning to predictable and unpredictable threats
      98. NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response
      99. NMDA-mediated social learning of fear-induced conditioned analgesia to biting flies
      100. NR2A-and NR2B-containing NMDA receptors in the prelimbic medial prefrontal cortex differentially mediate trace, delay, and contextual fear conditioning
      101. NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine
      102. PACAP modulates the consolidation and extinction of the contextual fear conditioning through NMDA receptors
      103. Pharmacological evidence that a failure to recruit NMDA receptors contributes to impaired fear extinction retention in adolescent rats
      104. Plasticity of NMDA receptors at Ventral Hippocampal Synapses in the Infralimbic Cortex Regulates Cued fear
      105. Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice
      106. Pre-training prevents context fear conditioning deficits produced by hippocampal NMDA receptor blockade
      107. Prefrontal NMDA receptors expressed in excitatory neurons control fear discrimination and fear extinction
      108. Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding
      109. Pretraining NMDA receptor blockade in the basolateral complex, but not the central nucleus, of the amygdala prevents savings of the conditional fear.
      110. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy
      111. ROLE OF PREFRONTAL CORTICAL NMDA NR2B SUBTYPE receptor IN fear-AND WORKING-MEMORY
      112. Role of the basolateral amygdala and NMDA receptors in higher-order conditioned fear
      113. Role of the basolateral amygdala and NMDA receptors in the acquisition and extinction of higher-order conditioned fear
      114. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory
      115. Second-order fear conditioning prevented by blocking NMDA receptors in amygdala
      116. Studies of GluN2C-containing NMDA receptors in schizophrenia-like behaviors and fear learning; Relevance to the glutamate hypofunction hypothesis of …
      117. Surface expression of hippocampal NMDA GluN2B receptors regulated by fear conditioning determines its contribution to memory consolidation in adult rats
      118. Targeting the NMDA receptor for fear-related disorders
      119. Temporal-difference prediction errors and Pavlovian fear conditioning: role of NMDA and opioid receptors.
      120. The effect of hippocampal NMDA receptor blockade by MK-801 on cued fear extinction
      121. The effect of the mGlu5 negative allosteric modulator MTEP and NMDA receptor partial agonist D-cycloserine on Pavlovian conditioned fear
      122. The effect of the NMDA receptor antagonist MK-801 on the acquisition and extinction of learned fear in the developing rat
      123. The effects of intra-hippocampal microinfusion of D-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the …
      124. The expression of contextual fear conditioning involves activation of a NMDA receptor-nitric oxide-cGMP pathway in the dorsal hippocampus of rats
      125. The expression of contextual fear conditioning involves activation of an NMDA receptor–nitric oxide pathway in the medial prefrontal cortex
      126. The importance of having Arc: expression of the immediate-early gene Arc is required for hippocampus-dependent fear conditioning and blocked by NMDA receptor …
      127. The innate defensive behaviour and unconditioned fear-induced antinociception evoked by NMDA receptor activation in the medial hypothalamus are modulated by …
      128. The nitric oxide donor SIN-1-produced panic-like behaviour and fear-induced antinociception are modulated by NMDA receptors in the anterior hypothalamus
      129. The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans
      130. The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning.
      131. The NMDA receptor antagonist MK-801 renders pavlovian fear conditioning state-dependent
      132. The role of dorsal hippocampus and basolateral amygdala NMDA receptors in the acquisition and retrieval of context and contextual fear memories.
      133. The role of GluN2B-containing NMDA receptors in short-and long-term fear recall
      134. The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear
      135. Trace and contextual fear conditioning require neural activity and NMDA receptor-dependent transmission in the medial prefrontal cortex
      136. Trace fear conditioning depends on NMDA receptor activation and protein synthesis within the dorsal hippocampus of mice
      137. US habituation, like CS extinction, produces a decrement in conditioned fear responding that is NMDA dependent and subject to renewal and reinstatement
      138. Vagus nerve stimulation enhances extinction of conditioned fear in rats and modulates Arc protein, CaMKII, and GluN2B-containing NMDA receptors in the …
      139. Vorinostat ameliorates impaired fear extinction possibly via the hippocampal NMDA-CaMKII pathway in an animal model of posttraumatic stress disorder
      140. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene
      Share
      0
      INTERSTELLAR BLEND

      Related posts

      January 3, 2023

      COSMECEUTICAL


      Read more
      January 3, 2023

      REMYELINATION


      Read more
      January 3, 2023

      NUTRACEUTICAL


      Read more

      Comments are closed.

      Recent Posts

      • COSMECEUTICAL
      • REMYELINATION
      • NUTRACEUTICAL
      • ANXIOGENIC
      • ECKLONIA CAVA
      © 2023 Interstellar Blends | Activate Your Super Powers!. © 2019 Interstellar Blends | Activate Your Super Powers!. All Rights Reserved.

      Mandatory FDA Disclaimer
      Privacy Policy
      Terms and Conditions
      Have Questions?
      Contact Gavin Robert McGowen Here

      Join the following facebook groups to learn more:
      Ultimate Weightloss Challenge , Dry Fasting, Longevity Agents , Interstellar Blend Seven Sages, The Infinitely Postive, THE INTERSTELLAR BLEND CHALLENGE: Fluid Restricted Fasting w/ Superherbs

      Love this Website? Contact David Rodriguez to build you one!